Ankle Sprain
Conditions
Brief summary
The primary purpose of this study is to assess the effectiveness of once daily application of a diclofenac sodium patch to the skin near or over the painful area. In this study, the location being studied will be either the left or right ankle. The secondary purpose of this study is to assess the safety and tolerability of a diclofenac patch on the skin.
Detailed description
Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.
Interventions
DRUGdiclofenac sodium
15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Sponsors
PPD Development, LP
Cerimon Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18 to 75 years of age * Has sustained a painful Grade 1 or 2 ankle sprain (Appendix H) no more than 48 hours prior to study entry * Presence of pain of at least 5, with a maximum of 9, on an 11-point Numerical Rating Scale (NRS)
Exclusion criteria
* Grade 3 ankle sprain or bilateral sprain (see Appendix H) * Previous injury to the same ankle within 3 months prior to current injury * Aspirin or short half-life NSAID use within 12 hours, or longer half-life NSAID use within 24 hours prior to study entry (Appendix B) * Opioid use within 24 hours prior to study entry * Topical treatment, other than ice packs, applied to the painful region since time of injury * A history of peptic ulcer disease within 1 year of study entry, any history of gastrointestinal bleeding or coagulation disorder * A history of, or evidence for, underlying disease in the injured ankle, such as osteoarthritis or gout * Clinically significant, poorly controlled pulmonary, gastrointestinal, hepatic, renal, endocrine, or cardiovascular disease * A history of hypersensitivity to diclofenac or diclofenac-containing products * A history of intolerance to acetaminophen (rescue medication in this trial) * A history of skin sensitivity to adhesives (e.g. adhesive tape) * Pregnant or breastfeeding women and women of child-bearing potential not using effective means of contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the efficacy of diclofenac in subjects with mild to moderate ankle sprain. | 7 days |
Secondary
| Measure | Time frame |
|---|---|
| Assess the safety and tolerability of diclofenac in subjects with mild to moderate ankle sprain. | 7 days |
Countries
United States
Outcome results
None listed